Mavacamten is a first-in-class selective allosteric modulator of beta cardiac myosin ATPase for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Victoria Fal
Advertisement
Articles by Victoria Fal
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Celebrating the Pharmacist’s Impact: How Pharmacists Elevate Care in Every Setting
3
FDA Approves 1-Minute HIV Self-Test
4
How Pharmacists Can Navigate Legal Complexities With Most Favored Nation Status
5
